Download PDF
Horm Metab Res 2013; 45(01): 69-73
DOI: 10.1055/s-0032-1321872
Humans, Clinical
© Georg Thieme Verlag KG Stuttgart · New York

A Vasodilating β1 Blocker Celiprolol Inhibits Muscular Release of Uric Acid Precursor in Patients with Essential Hypertension

E. Mizuta   *
1   Division of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Japan
,
S. B. Utami   *
2   Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
,
A. Ohtahara
3   Department of Cardiovascular Medicine, Sanin Rosai Hospital, Yonago, Japan
,
S. Endo
3   Department of Cardiovascular Medicine, Sanin Rosai Hospital, Yonago, Japan
,
M. Mishima
2   Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
,
A. Hasegawa
2   Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
,
K. Yamada
1   Division of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Japan
,
M. Kato
1   Division of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Japan
,
K. Yamamoto
1   Division of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Japan
,
K. Ogino
4   Center for Clinical Residency Program, Tottori University Hospital, Yonago, Japan
,
H. Ninomiya
5   Department of Biological Regulation, Tottori University Faculty of Medicine, Yonago, Japan
,
S. Miyazaki
6   Division of Cardiology, Nojima Hospital, Kurayoshi, Japan
,
T. Hamada
7   Department of Regional Medicine, Tottori University Faculty of Medicine, Yonago, Japan
,
S-i. Taniguchi
7   Department of Regional Medicine, Tottori University Faculty of Medicine, Yonago, Japan
,
J. Cheng
8   The First Affiliated Hospital of Shantou University Medical College, Shantou, China
,
I. Hisatome
2   Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
› Author Affiliations
Further Information

Publication History

received 22 April 2012

accepted 04 July 2012

Publication Date:
14 August 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Although nonvasodilating β1 blockers increase the levels of uric acid in serum, it is not known whether vasodilating β1 blockers have a similar effect. In the present study, we evaluated the effect of celiprolol on the release of hypoxanthine, a uric acid precursor, from muscles after an exercise. We used the semi-ischemic forearm test to examine the release of lactate (ΔLAC), ammonia (ΔAmm), and hypoxanthine (ΔHX) before and 4, 10, and 60 min after an exercise in 18 hypertensive patients as well as 4 normotensive subjects. Before celiprolol treatment, all the levels of ΔHX and ΔAmm, and ΔLAC were increased by semi-ischemic exercise in hypertensive patients, and the increases were remarkably larger than those in normotensive subjects. Celiprolol decreased both systolic and diastolic pressure. It also decreased the levels of ΔHX and ΔAmm without changes in ΔLAC after an exercise. These findings also were confirmed by summation of each metabolite (ΣΔMetabolites). Celiprolol caused a marginal decrease of serum uric acid, but the difference was not statistically significant. On the other hand, nonvasodilating β1 blockers did not suppress the levels of ΔHX and ΔAmm, whereas they significantly increased ΔLAC after an exercise. Celiprolol improved energy metabolism in skeletal muscles. It suppressed HX production and consequently did not adversely affect serum uric acid levels.

Key words

hypoxanthine - celiprolol - myogenic hyperuricemia - hypertension - exercise
* 

* E. Mizuta and S. B. Utami contributed equally to this project.


 

  • References

  • 1 Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
    CrossrefPubMedGoogle Scholar
  • 2 Yamamoto Y, Matsubara K, Igawa G, Kaetsu Y, Sugihara S, Matsuura T, Ando F, Sonoyama K, Hamada T, Ogino K, Igawa O, Shigemasa C, Hisatome I. Status of uric acid management in hypertensive subjects. Hypertens Res 2007; 30: 549-554
    CrossrefPubMedGoogle Scholar
  • 3 Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: The PIUMA study. Hypertension 2000; 36: 1072-1078
    CrossrefPubMedGoogle Scholar
  • 4 Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis D. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049
    CrossrefPubMedGoogle Scholar
  • 5 Shimada K, Fujita T, Ito S, Naritomi H, Ogihara T, Shimamoto K, Tanaka H, Yoshiike N. The importance of home blood pressure measurement for preventing stroke and cardiovascular disease in hypertensive patients: a sub-analysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. Hypertens Res 2008; 31: 469-478
    CrossrefPubMedGoogle Scholar
  • 6 Wang JG, Staessen JA, Fagard RH, Birkenhäger WH, Gong L, Liu L. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001; 37: 1069-1074
    CrossrefPubMedGoogle Scholar
  • 7 Guideline Revision Committee of the Japanese Society of Gout and Nucleic Acid Metabolism . Guideline for the management of hyperuricemia and. gout (second edition). Tokyo: 2010
    Google Scholar
  • 8 Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf B. LIFE Study Group . The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney International 2004; 65: 1041-1049
    CrossrefPubMedGoogle Scholar
  • 9 Aurell M, Bengtsson C, Björck S. Enalapril versus metoprolol in primary hypertension – effects on the glomerular filtration rate. Nephrol Dial Transplant 1997; 12: 2289-2294
    CrossrefPubMedGoogle Scholar
  • 10 Ohtahara A, Hisatome I, Yamamoto Y, Furuse M, Sonoyama K, Furuse Y, Hamada T, Katoh M, Watanabe M, Kinugawa T, Ogino K, Igawa O, Shimomura T, Murakami F, Yamamoto T, Shigemasa C. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by ACE inhibitor and alpha-1 blocker. J Hypertension 2001; 19: 575-582
    CrossrefPubMedGoogle Scholar
  • 11 Abe Y, Kaneko Y, Omae T, Kokubu T, Iimura O, Yoshinaga K. Clinical evaluation of celiprolol hydrochloride (NBP-582) for essential hypertension – A double-blind, parallel-group, comparative study using propranolol hydrochloride. J Clin Ther Med 1989; 5: 2321-2365
    PubMedGoogle Scholar
  • 12 Toda N. Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003; 100: 215-234
    CrossrefPubMedGoogle Scholar
  • 13 Tsukiyama H. Re-evaluation of β blockers for the treatment of hypertension. Ther Res 2010; 31: 431-453
    PubMedGoogle Scholar
  • 14 Israili ZH, Hernandez-Hernandez R, Valasco M. The future of antihypertensive treatment. Am J Ther 2007; 14: 121-134
    CrossrefPubMedGoogle Scholar
  • 15 Hisatome I, Yamamoto Y, Hamada T, Shigemasa C. Mechanism of the onset of hyperuricemia in patients with hypertension: Significance of the kidney-skeletal muscle-blood vessel network connected by nucleic-acid metabolites. Hyperuricemia Gout 2002; 10: 151-159
    PubMedGoogle Scholar
  • 16 Yamamoto Y, Sonoyama K, Matsubara K, Furuse M, Yatsuhashi T, Hamada T, Igawa O, Hisatome I, Shigemasa C. Analysis of the mechanisms of inhibitory effects against vascular remodeling with allopurinol. Gout Nucl Acid Metab 2001; 25: 137-139
    PubMedGoogle Scholar
  • 17 Juhlin-Dannfelt A, Frisk-Holmberg M, Karlsson J, Tesch P. Central and peripheral circulation in relation to muscle fiber composition in normo- and hypertensive men. Clin Sci 1979; 56: 335-340
    PubMedGoogle Scholar
  • 18 Higashiura K, Ura N, Takada T, Agata J, Yoshida H, Miyazaki Y, Shimamoto K. Alteration of muscle fiber composition linking to insulin resistance and hypertension in fructose-fed rats. Am J Hypertens 1999; 12: 596-602
    CrossrefPubMedGoogle Scholar
  • 19 Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?. Am J Hypertens 1998; 11: 1258-1265
    CrossrefPubMedGoogle Scholar
  • 20 Asanuma H, Node K, Minamino T, Sanada S, Takashima S, Ueda Y, Sakata Y, Asakura M, Kim J, Ogita H, Tada M, Hori M, Kitakaze M. Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release. J Cardiovasc Pharmacol 2003; 41: 499-505
    CrossrefPubMedGoogle Scholar
  • 21 Kimura K, Suzuki N, Omata M, Mise N, Oba S, Miyashita K, Kamijo A, Tojo A, Hirata Y, Goto A, Omata M. Vasodilating effects of celiprolol, a beta-adrenoceptor blocker, on renal microcirculation in rats. Curr Ther Res 1999; 60: 31-36
    CrossrefPubMedGoogle Scholar
  • 22 Hisatome I, Tsuboi M, Hamada T. Investigation on pathological conditions of hyperuricemia in patients with cardiovascular disease: Clinical significance of exercise-induced hyper-hypoxanthinemia in patients with hypertension. Gout and Nucleic Acid Metabolism 1999; 23: 187-193
    PubMedGoogle Scholar
  • 23 Hamada T, Yamamoto T, Hisatome I. Hyperuricemia in patients with hypertension. Hyperuricemia and Gout 2003; 11: 54-58
    PubMedGoogle Scholar